Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

NCT05886075 is registered in ClinicalTrials.gov with Shanghai Yunying Medical Technology as lead sponsor.

NCT NCT05886075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Lead sponsor
Shanghai Yunying Medical Technology
Phase
Phase 1
Overall status
Unknown status
Start date
March 30, 2023
Completion date
March 31, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, bronchial cancer, colorectal cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer, sarcoma, small cell lung cancer